Printer Friendly

Baxter International receives approval for FEIBA.

M2 EQUITYBITES-December 23, 2013-Baxter International receives approval for FEIBA

(C)2013 M2 COMMUNICATIONS http://www.m2.com

It was reported on Friday that Baxter International, a United States-based healthcare company, has received approval for its FEIBA (Anti-Inhibitor Coagulant Complex) from the US Food and Drug Administration.

The product is reportedly the first and only FDA-approved treatment for routine prophylaxis to prevent or decrease the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

The approval is based on data from a Phase III trial known as FEIBA PROOF, under which treatment with a FEIBA prophylactic regimen indicated a 72% reduction in median annual bleed rate against treatment with an on-demand regimen.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 23, 2013
Words:128
Previous Article:NuStar's board elects Tom Shoaf as successor to retiring CFO Steve Blank.
Next Article:Orion signs license agreement with Janssen.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters